CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Joseph D. MalaerInstitute for Molecular Medicine, University of North Texas Health Science Center3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USAPorunelloor A. MathewInstitute for Molecular Medicine, University of North Texas Health Science Center3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA
2017en
ABI
Аннотация
CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.
Перевод пока недоступен
Цитирования и источники
Цитирований: 3Использованных источников: 0